<DOC>
	<DOCNO>NCT00000102</DOCNO>
	<brief_summary>This study test ability extend release nifedipine ( Procardia XL ) , blood pressure medication , permit decrease dose glucocorticoid medication child take treat congenital adrenal hyperplasia ( CAH ) .</brief_summary>
	<brief_title>Congenital Adrenal Hyperplasia : Calcium Channels Therapeutic Targets</brief_title>
	<detailed_description>This protocol design ass acute chronic effect calcium channel antagonist , nifedipine , hypothalamic-pituitary-adrenal axis patient congenital adrenal hyperplasia . The multicenter trial compose two phase involve double-blind , placebo-controlled parallel design . The goal Phase I examine ability nifedipine vs. placebo decrease adrenocorticotropic hormone ( ACTH ) level , well begin assess dose-dependency nifedipine effect . The goal Phase II evaluate long-term effect nifedipine ; , attenuation ACTH release nifedipine permit decrease dosage glucocorticoid need suppress HPA axis ? Such decrease would , turn , reduce deleterious effect glucocorticoid treatment CAH .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>diagnose Congenital Adrenal Hyperplasia ( CAH ) normal ECG baseline evaluation history liver disease , elevate liver function test history cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2004</verification_date>
</DOC>